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Patients with refractory epilepsy (RE) have increased risk of Sudden Unexpected Death in Epilepsy (SUDEP), 
where acute and fatal heart failure is suspected. High seizure frequency, polypharmacy, changes in dosing, 
persistent low AED levels or poor adherence to therapy are the greatest risk factors of SUDEP and are also 
features observed in RE. We evaluated the progressive P-gp overexpression in heart, related with the development 
of fatal status epilepticus (FSE) after experimental repetitive seizures (ERS). Male Wistar rats (180–230g) were 
daily injected (i.p) with Pentylenetetrazole (PTZ; 45mg/kg; n=18) or saline (Controls; n=6). Severity of seizures 
was recorded. Four PTZ-treated rats were sacrificed at 4
th
-7
th
 day respectively. Ten remaining rats, underwent 
same treatment until develop fatal status epilepticus (FSE). Brains and hearts were studied by immunofluorecent 
method for P-glycoptrotein (P-gp) expression. Seizures were observed each day of PTZ treatment, associated with 
a progressive P-gp overexpression in heart and FSE at 9
th
 day. Using the same PTZ model, we previously 
demonstrated that progressive brain P-gp overexpression contributes to cell membrane depolarization of 
hippocampus and neocortex. These are the first evidences showing that ERS induces a simultaneous and 
progressive P-gp overexpression in brain and heart associated with FSE, and suggests a role for this pattern 
expression of P-gp as risk factor for death during SE. The simultaneous and spontaneous death of all animals 
during SE observed only at day 9
th
, suggest that a higher P-gp overexpression in cardiomyocytes could play a role 
in SUDEP, however, because it is only a study descriptive, further researches are needed to confirm this 
hypothesis. 
Keywords:  P-glycoptrotein; repetitive seizures; pentylenetetrazol; SUDEP; status epilepticus; myocardium 
Molecular & Cellular Epilepsy 2014; 1:43-51. doi: 10.14800/mce.66; © 2014 by Smart Science & Technology, LLC. 
 
 
EXPERT  RESEARCH ARTICLE 
 Jeró nimo Auzmendi, et al.  
 Progressive heart P-glycoprotein and SUDEP  
 
44 
 
Introduction 
Epilepsy carries an increased mortality risk of 
approximately two or three times the general population. 
This issue is even more critical in the subgroup of 
patients with drug-resistant epilepsy, where mortality rate 
is more elevated than in patients with well-controlled 
seizures and it has emerged as a major public health issue 
over the last decade 
[1-3]
. Sudden Unexpected Death in 
Epilepsy (SUDEP) is defined as sudden, unexpected, 
witnessed or unwitnessed, no traumatic and no drowning 
deaths in patients with epilepsy, in which post-mortem 
examination does not reveal a toxicological or anatomical 
cause of death 
[4]
.   
Several studies have attempted to identify clinical 
characteristics of patients with epilepsy at particular risk 
for SUDEP. Interestingly, long history of epilepsy 
(defined as more than 15 years), high seizure frequency 
(defined as more than 15 seizures per month), 
antiepileptic drug (AED) polypharmacy or frequent 
changes in dosing, persistent low plasma levels of AEDs 
or poor adherence to pharmacotherapy, are defined as the 
greatest risk factors of SUDEP that appears to correlate 
with the severity of the epilepsy 
[5-8]
. 
Because several of these features are associated to 
pharmacoresistant epilepsy, it is not surprising that 
SUDEP should be more likely to occur in patients who 
have developed refractory epilepsy (RE) phenotype 
[9-12]
. 
A main emerging mechanism to explain RE is the 
increased brain expression and/or function of multidrug 
transporter proteins, particularly the P-glycoptrotein (P-
gp), the product of the multidrug resistance protein 1 
(MDR1) gene 
[13-16]
.  
It has been previously demonstrated that experimental 
repetitive seizures (ERS) by daily administration of 3-
mercapto-propionic acid (3-MP), induce a progressive 
increase of P-gp brain expression, affecting not only the 
blood-brain barrier (BBB) cells, but also astrocytes and 
neurons 
[16]
. P-gp expression is increased in BBB vessels 
and related astrocytes after 4 days of 3-MP treatment, 
while neurons were highly immunoreactive after the 7
th
 
3-MP administration. In this experimental model, animals 
showed a progressive loss of protective effects of 
phenytoin (PHT) 
[17]
, whereas nimodipine, a P-gp 
inhibitor, restores the altered hippocampal PHT 
pharmacokinetics and reverted the refractory phenotype) 
[18]
. In addition, the continuous daily 3-MP-induced 
seizures resulted in PHT-refractory fatal status 
epilepticus (FSE) at day 13
th
, except in animals treated 
with Nimodipine plus PHT) 
[19]
.    
Although epilepsy and SE are, by definition, not 
causes of death, seizure activity can induce cardiovascu-
lar alterations (severe ictal tachycardia and abnormalities 
of the heart rhythm or repolarization) and changes in the 
respiratory rate and pattern including tachypnea, 
hypopnea or apnea) 
[20]
, all of them risk factors of heart 
ischemia
[21]
. The exact pathophysiological causes of 
SUDEP are unknown but it is very likely that 
cardiovascular and respiratory abnormalities during and 
between seizures, play a potential role. 
On the other hand, a group of evidence indicates that 
P-gp can also decrease plasma membrane potential of 
several cell types 
[22,23]
 and modulates the swelling-
activated chloride currents, both physiologic disturbances 
observed during brain and convulsive stress
[24-26]
. 
Recently, we demonstrated that progressive P-gp brain 
overexpression secondary to repetitive seizures induced 
by pentylenetetrazol (PTZ) in rats, contributes to an also 
progressive cell membrane depolarization of hippocamus 
and neocortex 
[27]
. On the other hand, since SUDEP has 
been related to mechanisms similar to those of sudden 
cardiac death, it has been suggested that cardiovascular 
alterations are associated to SUDEP 
[28]
.   
Based on the mentioned background, we designed 
experiments to determine if seizures induced after daily 
PTZ administration are associated to simultaneous and 
progressive increase of P-gp expression in brain and 
heart, and FSE.  
Material and methods 
PTZ and propidium iodure were obtained from Sigma 
Chemical (St. Louis, MO). All other chemical substances 
were of analytical grade.   
a. Animals and PTZ-induced seizures: Male Wistar 
rats (n=18), weighing 180–230 g. were maintained for at 
least 1 week on a 12-h diurnal cycle before use. Then, 
they were daily i.p. injected with a single dose of PTZ 
(45 mg/kg dissolved in saline solution). The severity of 
the seizures was rated according the following criteria: 
Grade I: Clonic seizures of forelimbs and some tonic 
jerks of hindlimbs; Grade II: Tonic-clonic seizures with 
clearly defined interictal episodes; Grade III: Tonic-
clonic seizures and SE, characterized by long lasting 
episode of convulsive activity, usually ending in a tonic 
hyperextension of all limbs with further recovery; Grade 
IV: SE with very short or absent interictal periods and 
death. 
The latency and duration of the different behavioral 
changes and incidence of death were daily recorded in 
each animal. Values of days 1, 4 and 7 were compared. 
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After 4 or 7 days of treatment, 4 rats with seizures Grade 
I-II were sacrificed in each time (PTZ-4, n=4; PTZ-7, 
n=4) respectively. Rats from PTZ4 or PTZ-7 groups were 
sacrificed one day after the last injection.  The remaining 
ten rats were daily administered with PTZ up to present 
FSE and surgically treated after death, for heart removal.  
As control for PTZ-4 and PTZ-7 groups, rats were 
daily injected i.p. with saline (1 ml/kg, i.p.) and then 
sacrificed after 4 (n=2) and 7 administrations (n=2). Two 
additional rats were sacrificed at day 9
th
 and used as 
control of the FSE group. Animals were anaesthesized 
and fixed by perfusion for the immunohistochemical 
studies as indicated later.    
The animal s´ care for this experimental protocol was 
in accordance with the NIH guidelines for the Care and 
Use of Laboratory Animals and the principles presented 
in the Guidelines for the Use of Animals in Neuroscience 
Research by the Society for Neuroscience.  
b. Tissue preparation: All brains and hearts were 
surgically removed and were placed in methyl-butane and 
frozen in dry ice. Frozen sections of 12 μm were cut in a 
cryostat, thaw-mounted on gelatin-coated slides, and 
stored at −70◦C until the day of incubation. 
 c. Immunostaining: Tissue sections of control and 
experimental groups were simultaneously processed by 
immunofluorescent method. Initially, they were washed 
with PBS-Triton (PBS buffer containing 0.025% Triton 
X-100) for 15 minutes. Then, they were blocked during 1 
h with normal horse serum (1:200) in buffer PBS. 
Antibodies were dissolved in PBS containing 1% v/v 
normal horse serum and 0.3% v/v Triton X-100, pH 7.4. 
The sections were initially incubated with anti-P-gp 
primary antibody (C-494 at a final concentration of 
1:500) for 48 h at 4°C, and then with fluorescent antibody 
anti-mouse conjugated (1:200) for 3 h (32). The contrasts 
were made with propidium iodure. Controls for the 
immunostaning procedure, routinely performed by 
omitting the primary antibody, did not develop any 
labeling. Anti-P-gp monoclonal antibody clone C494 was 
obtained from (Signet Laboratories, Dedham, MA) and 
fluorescent antibody anti-mouse IFTC conjugated was 
obtained (Zymed Lab Inc. San Fransisco, USA). Axio-
photmicroscope and fluorescent pictures were taken in an 
Olympus BX-50 microscope equipped with a digital 
cooled camera (Coolpix). Figures were made with Adobe 
Photoshop 7.0 software. 
d- Statistics: Individual experiments were composed of 
6–10 tissue sections of each animal from each group. In 
all tissue sections quantification of P-gp immunostaining 
were recorded by arbitrary units of optical density and % 
of surface market, and differences among the means were 
analyzed using one-way ANOVA and Student–Newman–
Keuls post test. Statistical significance was set to p<0.05. 
Values represent the means of 3–4 independent experi-
ments.  
Results and Discussion  
All animals treated with PTZ developed seizures 
according with the severity scale used. Briefly, rats from 
PTZ-4 developed seizures grade I-II, while animals from 
PTZ-7 developed seizures grade I-II (n=12) or grade III 
(n=2), and remained alive. All animals with longer time 
of PTZ administration (n=10) developed seizures grade 
IV at 9
th
 day, when died during SE. No significant 
differences in latencies were observed and the duration of 
seizures. However, a tendency to higher severity of scale 
used was observed from PTZ-7 group in 2 rats and in all 
rats at day 9
th
 (Table 1).   
In both brain and heart (pericardium, myocardium and 
endocardium) of control group, a basal expression of P-
gp was detected, however a progressive increasing of this 
expression was observed in both tissues of all animals 
according with the number of days treated with PTZ 
(Figure 1). A details of this increased immunostaining is 
observed in pericardium at day 4 (Figure 2), and in 
myocardium and endocardium at days 4 and 7 (Figures 3 
and 4). The effect was more evident in PTZ-7 group than 
in PTZ-4, when compared with control as evidenced by 
quantification of P-gp immunostaining in myocardium of 
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Figure 1. Progressive P-gp expression in neocortex and 
myocardium after repetitive seizures. Scale bar, 30 μm.  
 
Figure 2. P-gp expression in endocardium in control and 
PTZ4 groups. (PI: propidium iodine). Scale bar, 30 μm. 
control and PTZ treated rats (Figure 5). In FSE group, a 
similar pattern expression of P-gp in myocardium as in 
the PTZ-7 group was observed (Figure 7). Coincidently, 
a high increase of % of surface label was evident in 
myocardium of both, PTZ-7 and FSE groups (Figures 5 
and 8).  
Pattern expression of P-gp immunostaining in brain 
(neoccortex) of these animals (Figure 1) were similar to 
previously reported 
[27]
, and here we also show that the % 
of surface label in brain was PTZ-7>PTZ-4>controls 
(Figure 6), and this pattern was similar to the detected in 
myocardium (Figure 5).  
In our study, three main observations are remarkable 
related with repetitive convulsive seizures induced by 
 
Figure 3. P-gp expression in myocardium in Control, PTZ4 
and PTZ7 groups. (PI: propidium iodine).  Scale bar, 30 
μm. 
 
Figure 4. P-gp expression in pericardioum in Control, PTZ4 
and PTZ7 groups. (PI: propidium iodine). Scale bar, 30 μm. 
 
Figure 5. Image quantification of P-gp immunostaining in 
myocardium of control, PTZ-4 and PTZ-7 groups.  a: Optical 
density; b:surface label (%). 
PTZ. 
a: The progressive worsening in the severity of crises 
leading to FSE at 9
th
 day. 
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Figure 6. Image quantification of P-gp immunostaining in 
hippocampus of control, PTZ-4 and PTZ-7 groups. a-Optical 
density; b-surface label (%).  
Results corresponding to unpublished data from an additional 
study experimental repetitive seizure induced after daily 
consecutive doses of PTZ (see ref: 28). 
 
Figure 7. Arrows indicate high P-gp immunostaining in 
myocardium FSE as compared with negative immunostaining in 
control. Scale bar, 30 μm. 
 
Figure 8. Image quantification of P-gp immunostaining in 
myocardium of control and FSE.  a-Optical density; b-surface 
label (%). 
b:The simultaneous and progressive induction of P-gp 
expression in cells of brain and heart. 
c: FSE was associated with higher P-gp expression in 
heart observed in all animals at 9
th
 day. 
The first concept is in agreement with previous results 
reported from our and other groups suggesting that 
progressive increased brain expression of P-gp can be 
induced by convulsive stress 
[16,29-32]
, where repetitive 
seizures, recruit more P-gp-positive neurons, inducing a 
progressive depolarization and encouraging the 
development of increasingly severe crisis 
[27]
, and 
triggering a FSE 
[19]
.  
 In the second point, it is important to highlight that the 
in normal heart, P-gp is absent or it is only expressed in 
endothelial cells of capillaries and arterioles, but not in 
cardiomyocytes 
[33,34]
. Furthermore, P-gp overexpression 
in cardiomyocytes has been reported after both chronic 
and acute hypoxia-ischemic, and related with heart 
stunning 
[35,36]
. 
At date, there are no reports showing cardiac P-gp 
overexpression after convulsive stress. So, our current 
data represent the first evidence showing a progressive 
expression of P-gp in heart secondary to repetitive 
seizures, an effect that appears to be increased according 
with the number and/or severity underwent seizures.  
Interestingly the P-gp expression in heart observed under 
control situation was restricted to membranes of vascular 
cells of myocardium as described in normal humans 
[33]
.  
However, after repetitive seizures, a progressive 
increased expressing of P-gp was evident in cells of 
neocortex, pericardium, myocardium and endocardium 
(Figures 1-4).  
It was not surprising to see an increased expression of 
P-gp in brain cells upon to convulsive stress as previously 
described 
[16,29-32]
.  
Nevertheless, and similarly to the previously 
demonstrated in brain 
[27]
, the news is the P-gp expression 
in heart was higher in samples from PTZ-7 group than 
PTZ-4 group, indicating a parallelism between brain and 
heart of the progressive growing P-gp expression. 
Together, all these results suggest that during epilepsy, 
systemic factors involved in the up-regulation of MDR-1 
gen in heart as well as other peripheral associated organs 
could be related with the severity of the epilepsy. 
Furthermore, in an elegant experiment related with an 
altered phenytoin (PHT) pharmacokinetics, was 
documented the simultaneous high P-gp expression in 
different brain regions and liver of chronic epileptic rats 
[37]
. In this mentioned article and in the current 
experiment, a common finding of high P-gp expression in 
peripheral organs (liver and heart respectively) was 
detected after persistent and repetitive convulsive stress.   
Concerning the potentials mechanisms underlying the 
P-gp overexpression in heart, it was documented that 
convulsive stress, particularly tonic–clonic seizures and 
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prolonged tonic seizures can induce apnea and cyanosis, 
two well known hypoxic conditions 
[38,39]
.     
The continuous convulsive stress could mimic a 
repetitive apneas or hypoxia and produce heart ischemia. 
The MDR-1 gene is a survival rescue gene that can be 
up-regulated by several transcription factors including the 
Hypoxia Inducible Factor-1α (HIF-1α) 
[40]
, the paradigm 
of hypoxia responsive elements 
[41]
. 
According with this mechanism, it was previously 
demonstrated that high P-gp expression in 
cardiomyocytes is observed after chronic heart ischemic 
insults, as documented by 
99m
Tc-MIBI-SPECT 
[35]
. 
Additionally, in an acute ischemic-reperfusion  model,  
adult conscious sheep that underwent 12-min occlusion 
of the mid-left anterior descending artery followed by 
reperfusion, heart stunning was documented and high P-
gp expression in cardiomyocytes was also observed, as 
soon as 3 hours after experimental artery occlusion-
reperfusion procedure 
[36]
.  
Ischemia–reperfusion injury is a condition increasingly 
observed in clinical practice, given the widespread use of 
primary and rescue coronary angioplasty. When 
reperfusion occurs early enough to prevent cell death, the 
resulting feature is myocardial stunning 
[42]
 a 
phenomenon characterized by delayed recovery of 
ventricular contractile function despite successful 
reperfusion 
[43-45]
. Several mechanisms related with 
oxidative stress and perturbation of calcium homeostasis 
with intracellular free calcium overload described in heart 
stunning 
[42,43]
, are also observed in brain secondary to 
glutamate-dependent neurotoxicity 
[46]
. In spite it was 
suggested that cardiovascular effects are probably not the 
major cause of SUDEP 
[48]
, cardiac arrhythmias and 
cardiovascular changes are well documented during 
seizures and may be involved in some cases of SUDEP 
[35]
. 
In this regards, it was reported the potential 
pathomechanisms of SUDEP comprise cardiac arrhyth-
mia, due to electrolyte disturbances, arrhythmogenic 
drugs, or transmission of the epileptic activity via the 
autonomic nervous system to the heart, central or 
obstructive apnea, and myocardial ischemia 
[28]
. Further-
more, a variety of seizure-related cardiac dysrhythmias 
captured on ECG, including lengthening of the QT 
interval, ST depression and T-wave inversion, ventricular 
fibrillation and asystole,  bradyarrhythmias, as well as 
atrial fibrillation, atrial and ventricular premature depola-
rizations, and sinus and supraventricular tachycardias 
were documented. Additionally, seizure-related apnea 
and hypoxia may also play a central part in potentiating 
cardiac arrhythmias, with subsequent hypoxia acting as 
an additional contributing factor in cardio-respiratory 
arrest. Moreover, recently it was demonstrated that acute 
cardiovascular changes and death were observed after 
kainic acid-induced limbic cortical seizures in rats and 
was also suggested that the possibility of a coexisting 
“mild” susceptibility to sudden cardiac death, could be 
independent of the epilepsy, but which could becomes 
symptomatic in the presence of uncontrolled seizures 
[47,48]
. All these controversial data, indicates that more 
studied should be developed to better understanding of 
heart mechanisms involved in SUDEP or FSE. The 
biological role for P-gp over-expressed in heart, still 
remain to be investigated, and it could open a new 
paradigm on acute heart failure in FSE and/or SUDEP.  
Because P-gp over-expression also induce changes 
plasma membrane electrical potential producing 
membrane depolarization 
[22,23]
 it should be addressed 
related with electric function of the tissue or specific cells 
as neurons or cardiomyocytes. In our experiment we did 
not explored the cardiologic function, but taking in 
account all above mentioned, we speculate that the 
accumulative convulsive stress after repetitive seizure (no 
longer than few minutes), could also induce heart 
stunning. Under this hypothesis, the simultaneous 
seizure-dependent P-gp up-regulation in brain and heart 
observed, suggest a progressive risk to develop SE as we 
previously reported 
[17]
 and also could induce deleterious 
functional effects on heart. It could like a putative “mild” 
risk factor to develop cardiac failure as proposed in 
SUDEP and also under severe stress as occurring in SE. 
According with these observations, the mechanisms of 
sudden cardiac death in subjects with apparently normal 
hearts are poorly understood, however, seizure disorders 
were identified as co-morbid condition 
[49]
. In this 
regards, it was demonstrated that chronic supplementa-
tion with omega-3 fatty acid restored the heart rate of rats 
with epilepsy toward control values and suggest a 
potential preventive effect of omega-3 FA supplementa-
tion against SUDEP 
[50]
. Interestingly, a more recently 
published study demonstrated that omega-3 FA supple-
mentation reduced the amount of P-gp contained in 
multidrug-resistant cancer cells, decreased the transporter 
activity, and restored the antitumor effects of different 
chemotherapeutic drugs 
[51]
. 
In summary, our results are the first evidence 
indicating that P-gp can be induced to overexpress in 
heart secondary to repetitive seizures.   
Additionally, we can speculate that high P-gp expre-
ssion in brain 
[17,27]
 could play a role on the risk for SE 
development, and high P-gp expression in heart as 
demonstrated here, could play a role in the risk for 
develop an acute and fatal heart failure.  
Taking all data together, we believe that repetitive 
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seizures induce simultaneous P-gp overexpression in both 
brain and heart.  It could be a combined risk factor to 
develop an acute heart failure under severe stress 
triggered by SE resulting in a fatal final as FSE. Because 
our experiments are only a descriptive study, where 
mechanistic and functional studies on heart were not 
developed, this hypothesis should be confirmed with 
further investigations.     
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